BioLamina

Leland Conn DDS

🇮🇹 Italy

6.2

Reviewed: March 15, 2024

• - Clinical Protocol Design
• - 10 weeks January - March 2024
• - Pharmaceutical Company

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Guadalupe Franey

🇨🇭 Switzerland

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Miss Michelle Koch

🇪🇸 Spain

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Noah Pouros

🇺🇸 United States

9

Reviewed: June 9, 2024

• - Process Development
• - 12 weeks March - May 2024
• - Biotech Company

The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.

Dr. Clifford Howe

🇸🇦 Saudi Arabia

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.